Unique C1 Inhibitor Dysfunction in a Kindred without Angioedema

II. Identification of an Ala443→Val Substitution and Functional Analysis of the Recombinant Mutant Protein

Rana Zahedi, John Bissler, Alvin E. Davis, Charalambos Andreadis, Jeffrey J. Wisnieski

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We have determined the cause of an unusual C1 inhibitor abnormality in a large kindred. We previously found that half of serum C1 inhibitor molecules in affected kindred members are normal. The other half complexed with C1s but showed little complex formation with C1r. These molecules also appeared to be relatively resistant to digestion by trypsin. Taken together, the findings suggested that members of this kindred are heterozygous for an unusual C1 inhibitor mutation. Sequencing of genomic DNA from the kindred revealed that thymine has replaced cytosine in the codon for Ala443 (P2 residue) in one C1 inhibitor allele, resulting in substitution with a Val residue. To test the effect of this substitution, a mutant C1 inhibitor containing Ala443→Val was constructed by site-directed mutagenesis and expressed in COS-1 cells. Both the Ala443→Val mutant and the wild-type C1 inhibitor complexed completely with C1s, kallikrein, and coagulation Factor XIIa after incubation at 37°C for 60 min. In contrast, the mutant inhibitor failed to complex completely with C1r under the same conditions. Time course analysis showed that the ability of the mutant to complex with C1s is also impaired: although it complexed completely in 60 min, the rate of complex formation during a 0-60-min incubation was decreased compared with wild-type C1 inhibitor. The mutant inhibitor also formed a complex with trypsin, a serine protease that cleaves, and is not inhibited by, wild-type C1 inhibitor. The Ala443→Val mutation therefore converts C1 inhibitor from a substrate to an inhibitor of trypsin. These studies emphasize the role of the P2 residue in the determination of target protease specificity.

Original languageEnglish (US)
Pages (from-to)1299-1305
Number of pages7
JournalJournal of Clinical Investigation
Volume95
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Angioedema
Mutant Proteins
Recombinant Proteins
Trypsin
Factor XIIa
Mutation
Kallikreins
Thymine
Trypsin Inhibitors
COS Cells
Cytosine
Serine Proteases
Site-Directed Mutagenesis
DNA Sequence Analysis
Codon
Digestion
Peptide Hydrolases
Alleles
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Unique C1 Inhibitor Dysfunction in a Kindred without Angioedema : II. Identification of an Ala443→Val Substitution and Functional Analysis of the Recombinant Mutant Protein. / Zahedi, Rana; Bissler, John; Davis, Alvin E.; Andreadis, Charalambos; Wisnieski, Jeffrey J.

In: Journal of Clinical Investigation, Vol. 95, No. 3, 01.01.1995, p. 1299-1305.

Research output: Contribution to journalArticle

@article{95a606cecc064330835edc1da0249a53,
title = "Unique C1 Inhibitor Dysfunction in a Kindred without Angioedema: II. Identification of an Ala443→Val Substitution and Functional Analysis of the Recombinant Mutant Protein",
abstract = "We have determined the cause of an unusual C1 inhibitor abnormality in a large kindred. We previously found that half of serum C1 inhibitor molecules in affected kindred members are normal. The other half complexed with C1s but showed little complex formation with C1r. These molecules also appeared to be relatively resistant to digestion by trypsin. Taken together, the findings suggested that members of this kindred are heterozygous for an unusual C1 inhibitor mutation. Sequencing of genomic DNA from the kindred revealed that thymine has replaced cytosine in the codon for Ala443 (P2 residue) in one C1 inhibitor allele, resulting in substitution with a Val residue. To test the effect of this substitution, a mutant C1 inhibitor containing Ala443→Val was constructed by site-directed mutagenesis and expressed in COS-1 cells. Both the Ala443→Val mutant and the wild-type C1 inhibitor complexed completely with C1s, kallikrein, and coagulation Factor XIIa after incubation at 37°C for 60 min. In contrast, the mutant inhibitor failed to complex completely with C1r under the same conditions. Time course analysis showed that the ability of the mutant to complex with C1s is also impaired: although it complexed completely in 60 min, the rate of complex formation during a 0-60-min incubation was decreased compared with wild-type C1 inhibitor. The mutant inhibitor also formed a complex with trypsin, a serine protease that cleaves, and is not inhibited by, wild-type C1 inhibitor. The Ala443→Val mutation therefore converts C1 inhibitor from a substrate to an inhibitor of trypsin. These studies emphasize the role of the P2 residue in the determination of target protease specificity.",
author = "Rana Zahedi and John Bissler and Davis, {Alvin E.} and Charalambos Andreadis and Wisnieski, {Jeffrey J.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1172/JCI117780",
language = "English (US)",
volume = "95",
pages = "1299--1305",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Unique C1 Inhibitor Dysfunction in a Kindred without Angioedema

T2 - II. Identification of an Ala443→Val Substitution and Functional Analysis of the Recombinant Mutant Protein

AU - Zahedi, Rana

AU - Bissler, John

AU - Davis, Alvin E.

AU - Andreadis, Charalambos

AU - Wisnieski, Jeffrey J.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We have determined the cause of an unusual C1 inhibitor abnormality in a large kindred. We previously found that half of serum C1 inhibitor molecules in affected kindred members are normal. The other half complexed with C1s but showed little complex formation with C1r. These molecules also appeared to be relatively resistant to digestion by trypsin. Taken together, the findings suggested that members of this kindred are heterozygous for an unusual C1 inhibitor mutation. Sequencing of genomic DNA from the kindred revealed that thymine has replaced cytosine in the codon for Ala443 (P2 residue) in one C1 inhibitor allele, resulting in substitution with a Val residue. To test the effect of this substitution, a mutant C1 inhibitor containing Ala443→Val was constructed by site-directed mutagenesis and expressed in COS-1 cells. Both the Ala443→Val mutant and the wild-type C1 inhibitor complexed completely with C1s, kallikrein, and coagulation Factor XIIa after incubation at 37°C for 60 min. In contrast, the mutant inhibitor failed to complex completely with C1r under the same conditions. Time course analysis showed that the ability of the mutant to complex with C1s is also impaired: although it complexed completely in 60 min, the rate of complex formation during a 0-60-min incubation was decreased compared with wild-type C1 inhibitor. The mutant inhibitor also formed a complex with trypsin, a serine protease that cleaves, and is not inhibited by, wild-type C1 inhibitor. The Ala443→Val mutation therefore converts C1 inhibitor from a substrate to an inhibitor of trypsin. These studies emphasize the role of the P2 residue in the determination of target protease specificity.

AB - We have determined the cause of an unusual C1 inhibitor abnormality in a large kindred. We previously found that half of serum C1 inhibitor molecules in affected kindred members are normal. The other half complexed with C1s but showed little complex formation with C1r. These molecules also appeared to be relatively resistant to digestion by trypsin. Taken together, the findings suggested that members of this kindred are heterozygous for an unusual C1 inhibitor mutation. Sequencing of genomic DNA from the kindred revealed that thymine has replaced cytosine in the codon for Ala443 (P2 residue) in one C1 inhibitor allele, resulting in substitution with a Val residue. To test the effect of this substitution, a mutant C1 inhibitor containing Ala443→Val was constructed by site-directed mutagenesis and expressed in COS-1 cells. Both the Ala443→Val mutant and the wild-type C1 inhibitor complexed completely with C1s, kallikrein, and coagulation Factor XIIa after incubation at 37°C for 60 min. In contrast, the mutant inhibitor failed to complex completely with C1r under the same conditions. Time course analysis showed that the ability of the mutant to complex with C1s is also impaired: although it complexed completely in 60 min, the rate of complex formation during a 0-60-min incubation was decreased compared with wild-type C1 inhibitor. The mutant inhibitor also formed a complex with trypsin, a serine protease that cleaves, and is not inhibited by, wild-type C1 inhibitor. The Ala443→Val mutation therefore converts C1 inhibitor from a substrate to an inhibitor of trypsin. These studies emphasize the role of the P2 residue in the determination of target protease specificity.

UR - http://www.scopus.com/inward/record.url?scp=0028909546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028909546&partnerID=8YFLogxK

U2 - 10.1172/JCI117780

DO - 10.1172/JCI117780

M3 - Article

VL - 95

SP - 1299

EP - 1305

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -